Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor–Induced Interstitial Lung Disease Among Patients With Nonlung Cancers-Reference-Cited by-同舟云学术

Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor–Induced Interstitial Lung Disease Among Patients With Nonlung Cancers

Published:2020-11-12 Issue:11 Volume:3 Page:e2022906
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Shimoji Kiyofumi¹,Masuda Takeshi¹,Yamaguchi Kakuhiro¹,Sakamoto Shinjiro¹,Horimasu Yasushi¹,Nakashima Taku¹,Miyamoto Shintaro¹,Iwamoto Hiroshi¹,Fujitaka Kazunori¹,Hamada Hironobu¹,Takeno Sachio²,Hide Michihiro³,Teishima Jun⁴,Ohdan Hideki⁵,Hattori Noboru¹

Affiliation:

1. Department of Respiratory Internal Medicine, Hiroshima University Hospital, Minami-ku, Hiroshima, Japan

2. Department of and Otolaryngology and Head and Neck Surgery, Hiroshima University Hospital, Minami-ku, Hiroshima, Japan

3. Department of Dermatology, Hiroshima University Hospital, Minami-ku, Hiroshima, Japan

4. Department of Urology, Hiroshima University Hospital, Minami-ku, Hiroshima, Japan

5. Department of Gastroenterological and Transplant Surgery, Hiroshima University Hospital, Minami-ku, Hiroshima, Japan

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2772830/shimoji_2020_oi_200766_1604512873.81482.pdf

Reference24 articles.

1. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma.;Ansell;N Engl J Med,2015

2. Nivolumab for recurrent squamous-cell carcinoma of the head and neck.;Ferris;N Engl J Med,2016

3. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.;Kang;Lancet,2017

4. Nivolumab versus everolimus in advanced renal-cell carcinoma.;Motzer;N Engl J Med,2015

5. Nivolumab in previously untreated melanoma without BRAF mutation.;Robert;N Engl J Med,2015

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities;Cancer Immunology, Immunotherapy;2024-09-05

2. 18F-FDG-PET/CT Uptake by Noncancerous Lung as a Predictor of Interstitial Lung Disease Induced by Immune Checkpoint Inhibitors;Academic Radiology;2024-09

3. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis;Clinical Lung Cancer;2024-08

4. Immune mechanisms in fibrotic interstitial lung disease;Cell;2024-07

5. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis;The Oncologist;2024-06-17